Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

February 01, 1997; 48 (2) Brief Communication

Long-term follow-up of patients with subacute sclerosing panencephalitis treated with intraventricular alpha-interferon

Banu Anlar, Kalbiye Yalaz, Ferhunde Oktem, Gulsen Kose
First published February 1, 1997, DOI: https://doi.org/10.1212/WNL.48.2.526
Banu Anlar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kalbiye Yalaz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ferhunde Oktem
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gulsen Kose
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Long-term follow-up of patients with subacute sclerosing panencephalitis treated with intraventricular alpha-interferon
Banu Anlar, Kalbiye Yalaz, Ferhunde Oktem, Gulsen Kose
Neurology Feb 1997, 48 (2) 526-528; DOI: 10.1212/WNL.48.2.526

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
86

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Article abstract-We treated 22 patients with subacute sclerosing panencephalitis (SSPE) with intraventricular alpha-interferon (alpha-IFN) and oral inosiplex between 1986 and 1991. The follow-up for 56 to 108 months demonstrates a higher survival rate in these patients compared with those who did not receive alpha-IFN. However, eight of 11 patients whose condition improved after alpha-IFN treatment and five of five patients whose condition stabilized after alpha-IFN experienced neurologic deterioration 6 to 90 months after treatment; three of 11 and four of five died. The use of inosiplex did not influence the prognosis. Re-administration of the same regimen was not effective in one patient. Treatment-induced remissions in SSPE can be temporary, analogous to spontaneous remissions. Longer treatment with higher doses, or combinations of drugs, may be required.

NEUROLOGY 1997;48: 526-528

Subacute sclerosing panencephalitis (SSPE) has an invariably fatal course, although transient improvements or plateaus may occur and 20% of patients can survive 4 or more years. [1] We reported remission in 50% and stabilization in 22% of patients treated with intraventricular alpha-interferon (alpha-IFN) and oral inosiplex. [2] Others obtained similar results with this combination given in a different dose regimen. [3]

Spontaneous remissions are rare in SSPE. They may last 7 to 10 years. [4] The duration of remissions or improvements induced by alpha-IFN is unknown. We present the long-term follow-up of the first 22 patients treated with alpha-IFN and reported in 1992. [2]

Patients and methods.

The original group of 22 SSPE patients (15 boys, seven girls, aged 8-17 years, mean 12.5 +/- 2.6) treated with intraventricular alpha-IFN and oral inosiplex was followed up by neurologic examination, neurologic disability index (NDI), EEG, and psychometric tests done at various intervals for 54 more months after the initial report, total 56 to 108 months. Patients whose follow-up was incomplete were contacted by phone. The clinical staging system of Risk and Haddad [1] was used. The treatment regimen consisted of 6-week courses of natural alpha-IFN, started as 100,000 units/m sup 2 and increased to 1 million units/m2 body surface area per day, 5 days/week, given through an Ommaya reservoir. Courses were repeated up to six times, at 2 to 6-month intervals. Patients were also given oral inosiplex 50 to 100 mg/kg daily. [2]

The survival rate of the group taking alpha-IFN was compared with that of 35 other SSPE patients diagnosed during the same period (1986-1992) who did not receive alpha-IFN for various causes but did receive inosiplex or symptomatic treatment only. The age and sex distribution of the control group was similar to the treatment group: 25 boys and 10 girls, age 3 to 20, mean 11.2 +/- 3.9. The control group was followed up for 48 to 110 months.

Results.

Improvement or stabilization was observed in 16 patients initially (Table 1). In all patients whose NDI decreased with treatment (n = 11) the condition became stable in 3 to 12 months. Three remain in stable condition, with a follow-up of 56 to 104 months. The condition of the others (n = 8) began to deteriorate 12 to 84 months after treatment, and three of them died 20 to 90 months after treatment. One of these patients (case 15) was re-treated with the same regimen 1 year after deterioration started, but did not have a response. In the five patients in whom the condition initially stabilized, the disease also returned and progressed 6 to 60 months after treatment, and four died 8 to 66 months after treatment (Table 2). Clinical stage, age, duration of disease before alpha-IFN treatment, and inosiplex therapy did not influence the time and probability of later deterioration.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1. Data of patients treated with intraventricular alpha-IFN and oral inosiplex

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 2. Long-term results of the treatment group

The disease continued its progressive course after alpha-IFN treatment in six patients, although at a slower rate in three of them. Two patients who had the slowly progressive disease reached a stable condition 1 year after treatment and are still being followed up (56 and 90 months). The other patient with the slowly progressive disease died of meningitis while he was not receiving IFN, 14 months after treatment. Three patients in this group who died 3 to 12 months after treatment were included in the first report. [2]

The higher survival rate of IFN-treated patients compared with the control group persisted during 9 years of follow-up; however, the difference was smaller after 8 years (Figure 1). The use of inosiplex was not significantly different between the two groups: 13 patients in the alpha-IFN and 16 in the control group had received inosiplex for at least 6 months.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. Survival curves of patients treated with alpha-IFN and control cases.

Discussion.

Intraventricular alpha-IFN combined with oral inosiplex slowed or stopped the progressive course of SSPE, with a markedly increased chance of survival during the first 2 years after treatment. [2] This effect continued for several years, but at 9 years, the survival rate of patients treated with alpha-IFN was closer to that of untreated controls. Longer follow-up demonstrated that some remissions induced by alpha-IFN could be temporary, like spontaneous remissions. The recurrences were not influenced by inosiplex therapy. They tended to be more frequent and earlier among patients whose condition stabilized rather than improved after alpha-IFN, but the difference was not statistically significant. On the other hand, in two patients whose disease was slowly progressing after treatment, the disease became stable in one year; late remissions, although rare, seem possible.

The pathophysiology of remissions and relapses in SSPE is unknown. The stable state may depend on a balance between viral replication and immune response, and the immune system possibly has a role in remissions. CSF interferon levels were low in patients with SSPE [5] and their peripheral mononuclear cells failed to produce IFN in response to stimulation in in vitro experiments. [6] These findings suggest a deficient IFN system in SSPE. There may also be a relative resistance of the SSPE virus to IFN. [7] The effect of alpha-IFN treatment in SSPE may be mediated through these mechanisms. After a period of antiviral state induced by exogenous alpha-IFN, viral replication and propagation may increase due to acquired higher resistance, or to the presence of antibodies to IFN. The lack of response to re-treatment with alpha-IFN in one of our patients supports this possibility. We readministered alpha-IFN 1 year after she began to show late deterioration; we might have obtained better response with earlier treatment. The resistance to alpha-IFN might be overcome by higher doses given longer; two patients whose condition was deteriorating with alpha-IFN treatment became stabilized when the drug was given at higher doses and shorter intervals. [8]

Treatment in SSPE still requires further research, possibly including combinations of alpha-IFN with other agents. Among several immune modulators tested, Sobzyck et al. [9] observed the best results with Propionobacterium granulosum. [9] A single case report [10] suggested the efficacy of immune globulins, but our experience with immune globulins did not show any significant benefit (unpublished observations). Preliminary trials with beta-IFN are under way. Although its effect is limited, intraventricular alpha-IFN appears to be the most efficient therapeutic agent in the treatment of SSPE at present.

Acknowledgments

We thank Mehmet Okan, MD, and Bulent Coskun, MD, for their assistance in the follow-up of the patients and for their contribution to this study.

  • Copyright 1997 by Advanstar Communications Inc.

REFERENCES

  1. 1.↵
    Risk WS, Haddad FS. The variable natural history of subacute sclerosing panencephalitis: a study of 118 cases from the Middle East. Arch Neurol 1979;36:610-614.
    OpenUrl
  2. 2.↵
    Yalaz K, Anlar B, Oktem F, et al. Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis. Neurology 1992;42:488-491.
    OpenUrlPubMed
  3. 3.↵
    Gascon G, Yamani S, Crowell J, et al. Combined oral isoprinosine-intraventricular alpha-interferon therapy for subacute sclerosing panencephalitis. Brain Dev 1993;15:346-355.
    OpenUrlPubMed
  4. 4.↵
    Risk WS, Haddad FS, Chemali R. Substantial spontaneous long-term improvement in subacute sclerosing panencephalitis: six cases from the Middle East and a review of the literature. Arch Neurol 1978;35:494-502.
    OpenUrl
  5. 5.↵
    Lebon P, Boutin B, Dulac O, Ponsot G, Arthuis M. Interferon in acute and subacute encephalitis. BMJ 1988;296:9-11.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    Gadoth N, Kott E, Levin S, Hahn T. The interferon system in subacute scelerosing panencephalitis and its response to isoprinosine. Brain Dev 1989;11:308-312.
    OpenUrlPubMed
  7. 7.↵
    Crespi M, Chin MN, Schoub BD, Lyons SF. Effect of interferon on Vero cells persistently infected with SSPE virus and lytically infected with measles virus. Arch Virol 1986;90:87-96.
    OpenUrl
  8. 8.↵
    Kuroki S, Tsutsui T, Yoshioka M, et al. The effect of intraventricular interferon on subacute sclerosing panencephalitis. Brain Dev 1989;11:65-69.
    OpenUrlPubMed
  9. 9.↵
    Sobczyk W, Pilkowska E, Iwinska-Buksowicz B, Milewska D. Selective problems for katamnestic studies of SSPE patients 1980-89. Neurol Neurochir Pol 1994;28(Suppl 1):67-78.
  10. 10.↵
    Gurer YK, Kukner S, Sarica B. Intravenous gamma-globulin treatment in a patient with subacute sclerosing panencephalitis. Pediatr Neurol 1996;14:72-74.
    OpenUrlCrossRefPubMed

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Patients and methods.
    • Results.
    • Discussion.
    • Acknowledgments
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 98 (24)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise